Le Lézard
Classified in: Health
Subject: AWD

PharmaCielo Awarded Game-Changer Award by MJDaily


TORONTO and RIONEGRO, Colombia, Dec. 14, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., has been recognized with the prestigious MJ Biz Daily Game-Changer Award for the Latin America Region. The inaugural award was presented to the Company at a special gala, part of the MJ Biz Conference in Las Vegas, the world's largest cannabis conference and tradeshow. The award program recognizes global leaders, both companies and individuals, for their excellence and impact on the hemp and cannabis industries.

PharmaCielo (CNW Group/PharmaCielo Ltd.)

"We are tremendously honoured to receive this award, but even more thrilled that the panel of judges recognized PharmaCielo's role and contribution in paving the way and building the medical cannabis industry in Latin America," said David Attard, Chief Executive Officer, PharmaCielo Ltd. "Being an industry trailblazer is a challenging task. It means that whatever we do, every step of progress achieved, is a first for the industry, with the rule book written as we go. Now that we have laid the groundwork we are looking forward to a strong 2020 and expanding our existing presence throughout Latin America which began with Mexico, and which in 2019 added a number of others including both Uruguay and Argentina. This achievement is dedicated to PharmaCielo's employees who made this happen and who continue to maintain PharmaCielo and Colombia's positions as top players on the cannabis world stage."

About PharmaCielo
PharmaCielo Ltd. (TSXV: PCLO, OTCQX: PCLOF) is a global company, headquartered in Canada, with a focus on ethical and sustainable processing and supplying of all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its nursery and propagation centre located in Rionegro, Colombia.

The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia's ideal location will play in building a sustainable business in the medical cannabis industry, and the Company, together with its directors and executives, is executing on a business plan focused on supplying the international marketplace.

SOURCE PharmaCielo Ltd.


These press releases may also interest you

at 08:25
Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") today announced its second quarter 2020 financial results for the period ended June 30, 2020. "We are pleased by recent news releases from both Ipsen Pharmaceuticals and Elevation...

at 08:07
"Scientists, physicians and public health experts continue to learn about COVID-19 and how it is spread. We must use the limited tools we have today to slow the spread of the COVID-19 virus and minimize the damage it causes to individuals, our...

at 08:05
Pfizer Inc. today announced a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gilead's investigational antiviral remdesivir, as one of multiple external manufacturing organizations supporting efforts to scale up supply of...

at 08:05
Bruker Corporation today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.04 per share on the Company's common stock. The dividend will be paid on September 18, 2020 to stockholders of...

at 08:05
Senseonics Holdings, Inc. , a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced Highmark Inc. will begin...

at 08:05
Aimmune Therapeutics, Inc. , a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at...



News published on 14 december 2019 at 10:38 and distributed by: